A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

NCT06318884 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma, B-cell

Interventions

DRUG: SCTB35 injection

Sponsor

Sinocelltech Ltd.